Dimerix (ASX:DXB) Short Percentage of Float


ASX:DXB Dimerix Ltd ASX:DXB
32 GF Score
Price A$0.19
! 3 Warning Signs
View Full Analysis

What is Dimerix Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:DXB vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Dimerix's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dimerix Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dimerix's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Dimerix's Short Percentage of Float falls into.


ASX:DXB
32GF Score
Dimerix Ltd ASX:DXB
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimerix Business Description

Address 425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.
32GF Score

Get the complete analysis for ASX:DXB

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.19
Price